Ki Wan Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ki Wan Park has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Tulio A. Valdez
Department of Otolaryngology–Head & Neck Surgery Divisions Stanford University School of Medicine Stanford United States
3 shared publications- Emily C. Woods
Department of Pathology Stanford University School of Medicine Stanford United States
2 shared publications - Jeyun Jo
Department of Pathology Stanford University School of Medicine Stanford United States
2 shared publications - Jianghong Rao
Department of Radiology Molecular Imaging Program At Stanford Stanford University School of Medicine Stanford United States
2 shared publications - Matthew Bogyo
Stanford University School of Medicine
2 shared publications Shih‐Po Su
Department of Pathology Stanford University School of Medicine Stanford United States
2 shared publications
Latest Publications
- 30 April 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (24) , e9575966
Imaging of Staphylococcus aureus Infections and Biofilms Using a Selective Covalent Probe for the Unique Serine Hydrolase FphE
Staphylococcus aureus is the leading cause of soft tissue infections which can often be treated with antibiotics. However, it can also cause significant mortality and morbidity from systemic infections and infections of surgical implants. Implant infections typically require invasive surgery, and treatment often necessitates removal of the implant because S. aureus biofilms are extremely difficult to eradicate with antibiotic treatment alone. Therefore, there is a significant need for improved diagnostic tools for rapid, noninvasive confirmation of S. aureus infections. We recently developed an activity‐based probe containing an oxadiazolone electrophile that selectively and covalently labels the S. aureus ‐specific serine hydrolase, FphE. Here we describe a Cy5‐labeled version of the probe, JJ‐OX‐012, and its characterization as an imaging agent for detecting biofilms both in vitro and in vivo. The probe labeled S. aureus biofilms in vitro, with virtually no background labeling of bacteria that lack FphE expression, such as Escherichia coli . Furthermore, using a mouse surgical implant infection model, we demonstrate that JJ‐OX‐012 can be used for noninvasive fluorescent imaging to detect S. aureus biofilms in vivo. Overall, these findings support the potential for using covalent probes targeting FphE as imaging agents for rapid detection and diagnosis of staphylococcal infections in vivo.
- 30 April 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (24) , e9575966
Imaging of Staphylococcus aureus Infections and Biofilms Using a Selective Covalent Probe for the Unique Serine Hydrolase FphE
Staphylococcus aureus is the leading cause of soft tissue infections which can often be treated with antibiotics. However, it can also cause significant mortality and morbidity from systemic infections and infections of surgical implants. Implant infections typically require invasive surgery, and treatment often necessitates removal of the implant because S. aureus biofilms are extremely difficult to eradicate with antibiotic treatment alone. Therefore, there is a significant need for improved diagnostic tools for rapid, noninvasive confirmation of S. aureus infections. We recently developed an activity‐based probe containing an oxadiazolone electrophile that selectively and covalently labels the S. aureus ‐specific serine hydrolase, FphE. Here we describe a Cy5‐labeled version of the probe, JJ‐OX‐012, and its characterization as an imaging agent for detecting biofilms both in vitro and in vivo. The probe labeled S. aureus biofilms in vitro, with virtually no background labeling of bacteria that lack FphE expression, such as Escherichia coli . Furthermore, using a mouse surgical implant infection model, we demonstrate that JJ‐OX‐012 can be used for noninvasive fluorescent imaging to detect S. aureus biofilms in vivo. Overall, these findings support the potential for using covalent probes targeting FphE as imaging agents for rapid detection and diagnosis of staphylococcal infections in vivo.
- 30 April 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (24) , e9575966
Imaging of Staphylococcus aureus Infections and Biofilms Using a Selective Covalent Probe for the Unique Serine Hydrolase FphE
Staphylococcus aureus is the leading cause of soft tissue infections which can often be treated with antibiotics. However, it can also cause significant mortality and morbidity from systemic infections and infections of surgical implants. Implant infections typically require invasive surgery, and treatment often necessitates removal of the implant because S. aureus biofilms are extremely difficult to eradicate with antibiotic treatment alone. Therefore, there is a significant need for improved diagnostic tools for rapid, noninvasive confirmation of S. aureus infections. We recently developed an activity‐based probe containing an oxadiazolone electrophile that selectively and covalently labels the S. aureus ‐specific serine hydrolase, FphE. Here we describe a Cy5‐labeled version of the probe, JJ‐OX‐012, and its characterization as an imaging agent for detecting biofilms both in vitro and in vivo. The probe labeled S. aureus biofilms in vitro, with virtually no background labeling of bacteria that lack FphE expression, such as Escherichia coli . Furthermore, using a mouse surgical implant infection model, we demonstrate that JJ‐OX‐012 can be used for noninvasive fluorescent imaging to detect S. aureus biofilms in vivo. Overall, these findings support the potential for using covalent probes targeting FphE as imaging agents for rapid detection and diagnosis of staphylococcal infections in vivo.
- 30 April 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (24) , e9575966
Imaging of Staphylococcus aureus Infections and Biofilms Using a Selective Covalent Probe for the Unique Serine Hydrolase FphE
Staphylococcus aureus is the leading cause of soft tissue infections which can often be treated with antibiotics. However, it can also cause significant mortality and morbidity from systemic infections and infections of surgical implants. Implant infections typically require invasive surgery, and treatment often necessitates removal of the implant because S. aureus biofilms are extremely difficult to eradicate with antibiotic treatment alone. Therefore, there is a significant need for improved diagnostic tools for rapid, noninvasive confirmation of S. aureus infections. We recently developed an activity‐based probe containing an oxadiazolone electrophile that selectively and covalently labels the S. aureus ‐specific serine hydrolase, FphE. Here we describe a Cy5‐labeled version of the probe, JJ‐OX‐012, and its characterization as an imaging agent for detecting biofilms both in vitro and in vivo. The probe labeled S. aureus biofilms in vitro, with virtually no background labeling of bacteria that lack FphE expression, such as Escherichia coli . Furthermore, using a mouse surgical implant infection model, we demonstrate that JJ‐OX‐012 can be used for noninvasive fluorescent imaging to detect S. aureus biofilms in vivo. Overall, these findings support the potential for using covalent probes targeting FphE as imaging agents for rapid detection and diagnosis of staphylococcal infections in vivo.
- 24 January 2026
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 202, 112745
Tracheal cartilaginous sleeve prevalence in syndromic craniosynostosis: A single institution study
- 24 January 2026
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 202, 112745
Tracheal cartilaginous sleeve prevalence in syndromic craniosynostosis: A single institution study
- Open Access
Outcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study
Background: Sinonasal undifferentiated carcinoma (SNUC) is an extremely rare, high-grade, and aggressive tumor of the sinonasal tract. Due to the rarity of this malignancy, current treatment guidelines are based on small and often/mainly single-center retrospective datasets. In the absence of a universally accepted standard of care for SNUC, treatment approaches vary across countries and institutions, reflecting real-world clinical practice. The primary aim of this study was to describe real-world treatment and outcomes for patients with confirmed SNUC. Methods: This was an international, multi-center, retrospective, observational cohort study that pooled patients into the largest SNUC dataset to date. Fifteen centers were enrolled to contribute data, including seven from Europe, four from the United States, three from the United Kingdom, and one from Canada. In the absence of a universally accepted standard of care for SNUC, treatment approaches varied across countries and institutions, reflecting real-world clinical practice. Patients included were those with histologically confirmed SNUC who were treated between 1997 and 2021. Results: This study yielded 485 patients treated for SNUC. The median age at diagnosis was 55.6 years (IQR: 44.5–67.6), and 63.7% were male. Most cases presented at advanced stages, with 70.8% as T4a or T4b. Overall survival (OS) outcomes were available for 412 patients, with a median follow-up of 26.0 months. The 5- and 10-year OS were 47.2% (95% CI: 40.8–53.3%) and 39.6% (95% CI: 32.5–46.6%), respectively. Advanced age, dichotomized T-stage (T4a/b vs. T1–3), M-stage, and orbital involvement were significant poor prognostic factors on univariable analysis (p’s < 0.01). On multivariable analysis, orbital involvement (HR: 2.73, 95% CI: 1.42–5.27, p = 0.003) and distance metastasis stage (HR: 3.00, 95% CI: 1.25–7.21, p = 0.014) were both independently associated with worse OS. Conclusions: This observational study presents the largest multi-center cohort analysis of SNUC to date, providing new insights into prognostic factors for a rare cancer treated at global centers of excellence. Orbital involvement and the presence of metastases are candidate independent risk factors associated with poorer OS.
Open AccessOutcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study
Background: Sinonasal undifferentiated carcinoma (SNUC) is an extremely rare, high-grade, and aggressive tumor of the sinonasal tract. Due to the rarity of this malignancy, current treatment guidelines are based on small and often/mainly single-center retrospective datasets. In the absence of a universally accepted standard of care for SNUC, treatment approaches vary across countries and institutions, reflecting real-world clinical practice. The primary aim of this study was to describe real-world treatment and outcomes for patients with confirmed SNUC. Methods: This was an international, multi-center, retrospective, observational cohort study that pooled patients into the largest SNUC dataset to date. Fifteen centers were enrolled to contribute data, including seven from Europe, four from the United States, three from the United Kingdom, and one from Canada. In the absence of a universally accepted standard of care for SNUC, treatment approaches varied across countries and institutions, reflecting real-world clinical practice. Patients included were those with histologically confirmed SNUC who were treated between 1997 and 2021. Results: This study yielded 485 patients treated for SNUC. The median age at diagnosis was 55.6 years (IQR: 44.5–67.6), and 63.7% were male. Most cases presented at advanced stages, with 70.8% as T4a or T4b. Overall survival (OS) outcomes were available for 412 patients, with a median follow-up of 26.0 months. The 5- and 10-year OS were 47.2% (95% CI: 40.8–53.3%) and 39.6% (95% CI: 32.5–46.6%), respectively. Advanced age, dichotomized T-stage (T4a/b vs. T1–3), M-stage, and orbital involvement were significant poor prognostic factors on univariable analysis (p’s < 0.01). On multivariable analysis, orbital involvement (HR: 2.73, 95% CI: 1.42–5.27, p = 0.003) and distance metastasis stage (HR: 3.00, 95% CI: 1.25–7.21, p = 0.014) were both independently associated with worse OS. Conclusions: This observational study presents the largest multi-center cohort analysis of SNUC to date, providing new insights into prognostic factors for a rare cancer treated at global centers of excellence. Orbital involvement and the presence of metastases are candidate independent risk factors associated with poorer OS.
- 7 November 2025
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 47 (2) , e467-e472
Intraoperative Label-free Detection of Cholesteatoma Using Autofluorescence: A Feasibility Study
Objective: To evaluate the ability to distinguish cholesteatoma from surrounding tissues using autofluorescence intraoperatively. Study design: Prospective cohort study. Setting: Tertiary referral center. Patients: Patients with cholesteatoma undergoing middle ear surgery. Intervention: Autofluorescence imaging with 470 nm excitation light. Main outcome measure: Compare cholesteatoma autofluorescence with surrounding mucosa, bone, and granulation tissue. Results: A total of 6 patients undergoing cholesteatoma surgery were prospectively enrolled in the study for imaging. A custom-designed endoscopic and macroscopic imaging set-up utilizing 470 nm excitation was used to image the surgical field in real-time. Intraoperatively, autofluorescence imaging allowed delineation of cholesteatoma from surrounding bone, granulation tissue, and mucosa, even when cholesteatoma identification was difficult with white light alone. The 470 nm excitation was able to target endogenous fluorophores, specifically flavin adenine dinucleotide (FAD) and keratin, which are present within cholesteatoma, but not present in mucosa and granulation tissue. Conclusion: This study demonstrates the feasibility of autofluorescence-guided identification of cholesteatoma intraoperatively. The results support its potential as an adjunctive tool to surgeons for cholesteatoma identification.
- 7 November 2025
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 47 (2) , e467-e472
Intraoperative Label-free Detection of Cholesteatoma Using Autofluorescence: A Feasibility Study
Objective: To evaluate the ability to distinguish cholesteatoma from surrounding tissues using autofluorescence intraoperatively. Study design: Prospective cohort study. Setting: Tertiary referral center. Patients: Patients with cholesteatoma undergoing middle ear surgery. Intervention: Autofluorescence imaging with 470 nm excitation light. Main outcome measure: Compare cholesteatoma autofluorescence with surrounding mucosa, bone, and granulation tissue. Results: A total of 6 patients undergoing cholesteatoma surgery were prospectively enrolled in the study for imaging. A custom-designed endoscopic and macroscopic imaging set-up utilizing 470 nm excitation was used to image the surgical field in real-time. Intraoperatively, autofluorescence imaging allowed delineation of cholesteatoma from surrounding bone, granulation tissue, and mucosa, even when cholesteatoma identification was difficult with white light alone. The 470 nm excitation was able to target endogenous fluorophores, specifically flavin adenine dinucleotide (FAD) and keratin, which are present within cholesteatoma, but not present in mucosa and granulation tissue. Conclusion: This study demonstrates the feasibility of autofluorescence-guided identification of cholesteatoma intraoperatively. The results support its potential as an adjunctive tool to surgeons for cholesteatoma identification.
- Open Access
- 16 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (20) , 6555
Current and Emerging Therapies for Chronic Subjective Tinnitus
Importance: Chronic subjective tinnitus, the perception of sound without an external source for longer than six months, may be a greatly debilitating condition for some people, and is associated with psychiatric comorbidities and high healthcare costs. Current treatments are not beneficial for all patients and there is a large need for new therapies for tinnitus. Observations: Unlike rarer cases of objective tinnitus, chronic subjective tinnitus often has no obvious etiology and a diverse pathophysiology. In the absence of objective testing, diagnosis is heavily based on clinical assessment. Management strategies include hearing aids, sound masking, tinnitus retraining therapy, cognitive behavioral therapy, and emerging therapies including transcranial magnetic stimulation and electrical stimulation. Conclusions and relevance: Although current treatments are limited, emerging diagnostics and treatments provide promising avenues for the management of tinnitus symptoms.
- 16 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (20) , 6555
Open AccessCurrent and Emerging Therapies for Chronic Subjective Tinnitus
Importance: Chronic subjective tinnitus, the perception of sound without an external source for longer than six months, may be a greatly debilitating condition for some people, and is associated with psychiatric comorbidities and high healthcare costs. Current treatments are not beneficial for all patients and there is a large need for new therapies for tinnitus. Observations: Unlike rarer cases of objective tinnitus, chronic subjective tinnitus often has no obvious etiology and a diverse pathophysiology. In the absence of objective testing, diagnosis is heavily based on clinical assessment. Management strategies include hearing aids, sound masking, tinnitus retraining therapy, cognitive behavioral therapy, and emerging therapies including transcranial magnetic stimulation and electrical stimulation. Conclusions and relevance: Although current treatments are limited, emerging diagnostics and treatments provide promising avenues for the management of tinnitus symptoms.
- Open Access
- 8 September 2020
- Published by Hindawi Limited in Case Reports in Otolaryngology
- Vol. 2020, 1-4
Contrast-Induced Sialadenitis of the Sublingual Glands
Contrast-induced sialadenitis (CIS) is a rare, delayed pseudoallergic reaction from iodine containing contrast. Previously reported cases of CIS demonstrated that the two major salivary glands (parotid and submandibular) can be affected. The initial encounter of this entity can raise alarms to physicians as the differential diagnoses include serious infectious and inflammatory conditions such as Ludwig’s angina and angioedema. Subsequently, it may lead to unnecessary testing and increased healthcare cost. Here we present a 60-year-old male who presented with bilateral sublingual gland swelling following exposure to iodinated contrast. With timely diagnosis by the otolaryngologist, the patient received conservative management that led to a full resolution within a few days. To date, this is the first case of CIS only involving the sublingual glands. We conclude that CIS can involve any of the major salivary glands.
- 8 September 2020
- Published by Hindawi Limited in Case Reports in Otolaryngology
- Vol. 2020, 1-4
Open AccessContrast-Induced Sialadenitis of the Sublingual Glands
Contrast-induced sialadenitis (CIS) is a rare, delayed pseudoallergic reaction from iodine containing contrast. Previously reported cases of CIS demonstrated that the two major salivary glands (parotid and submandibular) can be affected. The initial encounter of this entity can raise alarms to physicians as the differential diagnoses include serious infectious and inflammatory conditions such as Ludwig’s angina and angioedema. Subsequently, it may lead to unnecessary testing and increased healthcare cost. Here we present a 60-year-old male who presented with bilateral sublingual gland swelling following exposure to iodinated contrast. With timely diagnosis by the otolaryngologist, the patient received conservative management that led to a full resolution within a few days. To date, this is the first case of CIS only involving the sublingual glands. We conclude that CIS can involve any of the major salivary glands.
- 5 March 2020
- Published by Wiley in The Laryngoscope
- Vol. 130 (12) , E833-E836
Round Cell Sarcoma with EWSR1‐PATZ1 Gene Fusion in the Neck: Case Report and Review of the Literature
EWSR1‐PATZ1 is a rare gene fusion recently recognized to occur in round and spindle cell sarcomas. To date, fewer than 20 cases have been described in the literature. However, no dedicated case reports have detailed its presentation in the head and neck region. We recently cared for a 52‐year‐old woman with an isolated, single right level 5A cervical mass. Excisional biopsy at an external hospital revealed pathology results consistent with EWSR1‐PATZ1 polyphenotypic round and spindle cell sarcoma. The patient subsequently underwent surgical excision of the tumor and right neck lymph node dissection followed by adjuvant chemoradiation. Laryngoscope, 2020
- 5 March 2020
- Published by Wiley in The Laryngoscope
- Vol. 130 (12) , E833-E836
Round Cell Sarcoma with EWSR1‐PATZ1 Gene Fusion in the Neck: Case Report and Review of the Literature
EWSR1‐PATZ1 is a rare gene fusion recently recognized to occur in round and spindle cell sarcomas. To date, fewer than 20 cases have been described in the literature. However, no dedicated case reports have detailed its presentation in the head and neck region. We recently cared for a 52‐year‐old woman with an isolated, single right level 5A cervical mass. Excisional biopsy at an external hospital revealed pathology results consistent with EWSR1‐PATZ1 polyphenotypic round and spindle cell sarcoma. The patient subsequently underwent surgical excision of the tumor and right neck lymph node dissection followed by adjuvant chemoradiation. Laryngoscope, 2020